Welcome to our dedicated page for Quest Diagnostics news (Ticker: DGX), a resource for investors and traders seeking the latest updates and insights on Quest Diagnostics stock.
Quest Diagnostics Incorporated (DGX) provides essential diagnostic insights and testing services across the U.S. healthcare system. This news hub aggregates official press releases, financial updates, and strategic developments from one of America's leading clinical laboratory networks.
Investors and healthcare professionals will find timely updates on earnings reports, partnership announcements, and technological advancements in diagnostic testing. Our curated news feed includes regulatory milestones, service expansions, and innovations leveraging DGX's vast clinical database.
Key updates cover emerging trends in precision diagnostics, laboratory network growth, and healthcare collaborations. Users can track the company's progress in cancer detection, genomic testing, and data-driven health solutions through verified primary sources.
Bookmark this page for direct access to DGX's latest financial performance data, leadership changes, and operational developments. Visit regularly to stay informed about how Quest Diagnostics continues shaping diagnostic medicine through clinical excellence and strategic initiatives.
Quest Diagnostics (NYSE: DGX) announced its participation in the Credit Suisse 30th Annual Healthcare Conference on November 9, 2021, at 9:40 a.m. ET. Mark Guinan, Executive Vice President and CFO, will discuss the company's vision and capital deployment strategies. The presentation will be available via a live webcast on the company's investor relations page, with an archived version accessible for 30 days post-event.
Quest Diagnostics is a leading provider of diagnostic services, serving one in three adult Americans and emphasizing their commitment to improving health outcomes through insights from clinical lab results.
Quest Diagnostics (NYSE: DGX) reported third-quarter financial results for 2021, revealing a modest net revenue of $2.774 billion, down 0.4% from the previous year. Despite a strong performance in COVID-19 molecular testing, operating income decreased by 9.3% to $652 million, with diluted EPS at $4.02, a 2.8% drop. However, year-to-date revenue increased 25% to $8.044 billion, driven by a significant 25.8% growth in diagnostic services. The company has raised its 2021 outlook, anticipating 10.7% to 12.3% revenue growth and adjusted EPS between $13.50 and $13.90.
Quest Diagnostics has entered an agreement with the Texas Department of State Health Services to provide COVID-19 testing services for K-12 schools, benefiting over 1,150 districts in Texas for the 2021-2022 school year. The program utilizes PCR and other nucleic acid amplification tests at Quest's clinical labs. Funding is provided through a CDC grant, ensuring no costs for schools or families. This initiative aims to promote safer in-person learning by enabling pooled testing.
On October 18, 2021, Quest Diagnostics announced it will provide clinical laboratory testing using the Ki-67 IHC MIB-1 pharmDx, a companion diagnostic for Verzenio (abemaciclib), following its FDA approval on October 13. Verzenio is the first CDK4/6 inhibitor approved for treating high-risk, HR+ HER2- early breast cancer patients. Quest, in partnership with Agilent Technologies, is the first lab to validate this test, aiming for national availability by month's end. This initiative underscores Quest's commitment to precision medicine in oncology.
Quest Diagnostics (DGX) has successfully integrated its Northeast operations at a new 250,000 sq. ft. lab in Clifton, NJ, serving over 40 million people annually. This facility is among the largest medical labs globally, capable of performing 300,000 tests per day with enhanced accuracy and efficiency. The lab represents a commitment of over $250 million, creating more than 1,000 jobs and showcasing advanced automation to improve diagnostic services. The facility can expand for increased testing demands, underscoring Quest's dedication to health innovations.
Quest Diagnostics (NYSE: DGX) has become the exclusive provider of onsite COVID-19 testing for the 125th Boston Marathon, scheduled for October 11, 2021. All participants must provide proof of vaccination or a negative test within 72 hours. The collaboration aims to ensure a safe event for runners, staff, and volunteers. Quest will manage testing events leading up to the marathon and offers testing through its QuestDirect service. This initiative highlights Quest Diagnostics' commitment to public health and safety during major events.
Quest Diagnostics (NYSE: DGX) announced it will release its third quarter 2021 financial results on October 21, 2021, before the market opens. A conference call is scheduled to begin at 8:30 a.m. ET on the same day, accessible via phone and webcast. Participants are encouraged to dial in 10 minutes early. A replay will be available until November 4, 2021. The company emphasizes its role in improving health outcomes through diagnostic insights, serving one in three adult Americans and half of U.S. physicians and hospitals.
According to a Quest Diagnostics study published in JAMA Pediatrics, over half (50.5%) of American children under six tested have detectable lead levels in their blood. The study analyzed data from 1,141,441 children and found that children in high-poverty areas and older housing are at greater risk. Although elevated blood lead levels (≥5.0 µg/dL) have declined to 1.9%, the persistent lead exposure remains a significant public health concern. Experts emphasize the need to eliminate all lead sources, given that no safe level of lead exposure in children has been identified.
Quest Diagnostics (DGX) updated its financial outlook for 2021 amid stronger-than-expected COVID-19 molecular testing volumes, driven by the Delta variant's surge. The company now anticipates net revenues between $9.84 billion and $10.09 billion, reflecting a 4.3% increase from prior expectations. Adjusted diluted EPS is projected to range from $11.65 to $12.35. The company also expects to generate at least $2 billion in cash from operations and maintain capital expenditures around $400 million. Factors affecting future results include the pandemic's duration and reimbursement rates.
The Quest Diagnostics Health Trends study reveals a significant decline in new cancer diagnoses during the initial phases of the COVID-19 pandemic. Analyzing data from 799,496 patients, the study indicates that from March 2020 to March 2021, cancer diagnoses fell by 29.8% during early pandemic months and continued to decline by 19.1% by March 2021. This decline raises concerns over undiagnosed cancers and emphasizes the need for regular preventive care. Medical professionals warn that delayed diagnoses could lead to more advanced cancers, necessitating aggressive treatment and resulting in poorer outcomes.